Drugs / S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03561181 | Jul 2017 → Jan 2018 | shigellosis | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05156528 | Dec 2021 → Jan 2024 | shigellosis | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05156528 ↗ |
| Modality | Vaccine | “S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine” NCT03561181 ↗ |
| Route | Intramuscular | “Single intramuscular dose” NCT03561181 ↗ |